Efficacy News and Research

RSS

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Researchers in the United States say the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant – P.1 – that has recently emerged in Brazil shows a worrying level of resistance to neutralization by antibodies.

4 Mar 2021

Experimental safety switch reduces severity of CAR-T immunotherapy-related side effects

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

4 Mar 2021

Innovative cancer treatment effective in combating fungal infection in vitro and in mice

An innovative cell-based treatment for cancer has been found promising for the control of infections caused by fungi.

4 Mar 2021

KHN’s ‘What the Health?’: Good and not-so-good news on Covid

There's good news and bad news on Covid-19 this week. On the one hand, several million doses of the one-shot Johnson & Johnson vaccine authorized by the FDA for emergency use are already going into the arms of people around the nation.

4 Mar 2021

Study reveals a small molecule inhibits SARS-CoV-2 infection in cells

Researchers found a small molecule that inhibits different virus proteins and significantly reduces infection in cells. Combined with the antiviral remdesivir, its potency increases significantly, suggesting it may be a potential antiviral candidate for the treatment of COVID-19.

4 Mar 2021

How Ecodyst’s Modern Rotovap Revolutionizes Rotovap Technology

In this interview, NewsMed talks to George Adjabeng about the revolutionary new rotovap, Ecodyst Hydrogen, and how it supersedes traditional rotovap models,

From Ecodyst 4 Mar 2021

Research looks at COVID vaccine hesitancy and refusal among the U.S. public

Vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rolled out in many countries, including the United States. As the number of coronavirus disease (COVID-19) cases continues to rise, vaccinating many people in the population is crucial. Despite campaigns to inform residents of the benefits of vaccines, many are still reluctant to get vaccinated.

4 Mar 2021

Intrapericardial injection provides a less invasive means of treating cardiac injury

Injecting hydrogels containing stem cell or exosome therapeutics directly into the pericardial cavity could be a less invasive, less costly, and more effective means of treating cardiac injury, according to new research from North Carolina State University and the University of North Carolina at Chapel Hill.

4 Mar 2021

Researchers discover a safe, effective, reversible male contraceptive agent

In a new paper published by Nature Communications, The Lundquist Institute (TLI) Investigator Wei Yan, MD, PhD, and his research colleagues spell out an innovative strategy that has led to the discovery of a natural compound as a safe, effective and reversible male contraceptive agent in pre-clinical animal models

4 Mar 2021

Study shows lower antibody cross-reactivity after infection with the B.1.1.7 SARS-CoV-2 variant

In a recent research paper currently available on the bioRxiv* preprint server, a diverse group of researchers has examined the immunogenicity of antibodies against the variant B.1.1.7 of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) initially found in the United Kingdom – and revealed diminished recognition and neutralization of either parental strains or the South African variant.

3 Mar 2021

Pfizer SARS-CoV-2 vaccine effective from day 11 post 1st vaccination

New research from a team of scientists in Australia finds that the second ‘booster’ dose of the Pfizer-BioNTech vaccine did not increase vaccine efficacy against severe acute respiratory syndrome (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). The results suggest one dose of the vaccine was sufficient in providing a robust immune response 11 days after inoculation.

3 Mar 2021

Using two different viruses to tackle tumors

An international research group led by the University of Basel has developed a promising strategy for therapeutic cancer vaccines.

3 Mar 2021

PICI awards $3 million to support early career cancer researchers

From improving immunotherapy response in childhood cancer patients, to better understanding how cancer's spread to the liver affects the body's immune system, to helping T cells stay energized to fight cancer, The Parker Institute for Cancer Immunotherapy (PICI)'s 2021 class of early career researchers award recipients are pursuing ideas that have the potential to change the face of oncology.

3 Mar 2021

UK public health authorities review early data on the effectiveness of Pfizer and AstraZeneca COVID-19 vaccines

A team of UK scientists has recently evaluated the effectiveness of the Pfizer (BNT162b2) and AstraZeneca (ChAdOx1) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The findings reveal that both vaccines are effective in significantly reducing SARS-CoV-2 infection in older adults and providing long-term protection.

3 Mar 2021

Researchers develop ultrapotent miniproteins that target SARS-CoV-2 receptor-binding domain

Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the miniprotein, LCB1, against SARS-CoV-2-mediated lung disease in human ACE2-expressing transgenic mice.

3 Mar 2021

Obesity may reduce COVID-19 vaccine efficacy, say researchers

A startling indicates that obesity may reduce the immune response to the current COVID-19 vaccines, along with other factors like age and sex. This could have significant implications for vaccination strategies in obese people.

3 Mar 2021

Delayed second dose strategy with mRNA vaccines may reduce COVID-19 mortality, say researchers

An interesting new preprint shows that even if countries are forced to delay the second dose of the current vaccines administered against SARS-CoV-2, to arrest the ongoing COVID-19 pandemic, the cumulative mortality would still fall significantly.

3 Mar 2021

Combination of therapies may benefit patients with mitochondrial respiratory chain disorders

Researchers from the Mitochondrial Medicine Frontier Program at Children's Hospital of Philadelphia (CHOP) have demonstrated how one combination of therapies may be beneficial for patients with mitochondrial respiratory chain disorders.

3 Mar 2021

A model of vaccine-derived herd immunity against COVID-19 in heterogeneous populations

A recent theoretical paper, currently available on the medRxiv preprint server, unveils a novel vaccination model that shows how a herd immunity threshold (HIT) value which considers heterogeneity is substantially lower in comparison with a HIT value of assuming a homogeneous population – with many implications for further vaccination planning.

2 Mar 2021

Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers

Researchers at the New York State Department of Health in the United States have said concerning mutations within the B.1.526 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently become prevalent in New York State warrant further monitoring.

2 Mar 2021

Efficacy News and Research

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Experimental safety switch reduces severity of CAR-T immunotherapy-related side effects

Innovative cancer treatment effective in combating fungal infection in vitro and in mice

KHN’s ‘What the Health?’: Good and not-so-good news on Covid

Study reveals a small molecule inhibits SARS-CoV-2 infection in cells

How Ecodyst’s Modern Rotovap Revolutionizes Rotovap Technology

Research looks at COVID vaccine hesitancy and refusal among the U.S. public

Intrapericardial injection provides a less invasive means of treating cardiac injury

Researchers discover a safe, effective, reversible male contraceptive agent

Study shows lower antibody cross-reactivity after infection with the B.1.1.7 SARS-CoV-2 variant

Pfizer SARS-CoV-2 vaccine effective from day 11 post 1st vaccination

Using two different viruses to tackle tumors

PICI awards $3 million to support early career cancer researchers

UK public health authorities review early data on the effectiveness of Pfizer and AstraZeneca COVID-19 vaccines

Researchers develop ultrapotent miniproteins that target SARS-CoV-2 receptor-binding domain

Obesity may reduce COVID-19 vaccine efficacy, say researchers

Delayed second dose strategy with mRNA vaccines may reduce COVID-19 mortality, say researchers

Combination of therapies may benefit patients with mitochondrial respiratory chain disorders

A model of vaccine-derived herd immunity against COVID-19 in heterogeneous populations

Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News